These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6734034)

  • 21. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS; Phillips AC; Rieutord A; Shenfield GM
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.
    Back DJ; Maggs JL; Purba HS; Newby S; Park BK
    Br J Clin Pharmacol; 1984 Oct; 18(4):603-7. PubMed ID: 6487500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
    Woolhouse NM; Eichelbaum M; Oates NS; Idle JR; Smith RL
    Clin Pharmacol Ther; 1985 May; 37(5):512-21. PubMed ID: 3987174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
    Inaba T; Tyndale RE; Mahon WA
    Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
    [No Abstract]   [Full Text] [Related]  

  • 28. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
    Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
    Groen K; Breimer DD; van Bezooijen CF
    Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 31. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cigarette smoking and theophylline clearance and metabolism.
    Grygiel JJ; Birkett DJ
    Clin Pharmacol Ther; 1981 Oct; 30(4):491-6. PubMed ID: 7285483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine.
    Mucklow JC; Caraher MT; Idle JR; Rawlins MD; Sloan T; Smith RL; Wood P
    Br J Clin Pharmacol; 1980 Mar; 9(3):283P. PubMed ID: 7362739
    [No Abstract]   [Full Text] [Related]  

  • 38. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 39. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.